|
1
|
- Richard F. Spark, MD, FACE
- Beth Israel Deaconess Medical Center
- Boston, MA
|
|
2
|
- 1984-DHEA ignored by FDA
- 1986-Rancho Bernardo-Low DHEA and CV
deaths
- 1994-DSHEA -DHEA an OTC
“supplement”
- 1999-DHEA-improves well-being + sexuality in women with adrenal insufficiency
- 2000-DHEA heightens sexuality in older women, not men
|
|
3
|
|
|
4
|
|
|
5
|
|
|
6
|
|
|
7
|
|
|
8
|
|
|
9
|
|
|
10
|
|
|
11
|
|
|
12
|
|
|
13
|
|
|
14
|
|
|
15
|
- Advocates
- E +T better than E
- a. bone density,
- b. GH and IGF
- c. Libido
- DHEA improves
- a. Well-being
- b. QOL
- c. Libido
- Skeptics
- Baseline T low ?
- Inc.T to young female range- no
- High normal T + resp
- AE’s
- DHEA
- Variable to no benefit
- Unreliable DHEA preps.
- AE’s
|
|
16
|
|
|
17
|
- NZB mice
- a.Prevents autoimmune
disease
- b. prolongs life
- Patients
- a. Pre- Rx. DS levels
suppressed
- b.DHEA improves SLEDAI scores
- c. Reduces Prednisone
requirement
- d.Up-regulates IL-2 production
|
|
18
|
- IL-6 levels increase as DHEA/DHEA-s levels decline in aging, RA, PMR,
osteopenia, atherosclerosis.
- Il-6 receptors in adrenal cortex
- Il-6 increases cortisol, DHEA/DHEAS while blunting ACTH.
- DHEA reverses endotoxin-mediated
IL-6 production
- Are immunosenescence and adreno-senescence co-dependent ?
|
|
19
|
|
|
20
|
|